Solutions for the Molecular Lab
The largest untapped inefficiency in genomics isn’t the sequencer or analysis — it’s the hidden compromises labs have been forced to accept over time.
Those compromises live upstream of the sequencer. Each is rational in the moment — together they compound, and as labs face mounting pressure to deliver cutting-edge testing at a viable cost per sample, they quietly cap the one thing that matters most: the ability to scale profitably.
The next unlock in the unit economics of genomics lies upstream of the sequencer.
For fifteen years the industry drove down the cost of sequencing — first through chemistry, then through dry-lab automation. The largest gain still on the table isn’t in either: it’s everything that happens before a single read is generated.
I’ve watched the impact of this throughout my career — labs regressing to send-out testing when the unit economics stopped working, technology implementations stalling for months, and in some cases labs closing their doors. The cause usually isn’t the technology itself; it’s an operations problem. E2E sample tracking held together by a spreadsheet, manual data entry between systems, overlapping system boundaries, custom code force-fitting platforms into work they were never designed for, a standing reliance on professional services — all of this drives the cost per sample/read well above what anyone estimated.
Three things drive it:
- Procurement requirements that were never properly scoped — the lab wrote a spec based on the need for one component and didn’t model how that component fits into their E2E workflow, both today and in the future.
- A workflow and total cost of ownership nobody modeled at the process level — high-level estimates leave out the nuance of a fully burdened cost analysis.
- Molecular labs are highly variable and constantly changing — which often results in custom code and shadow systems to fill the gap between system capability and operational needs.
Nobody chose these intentionally. They accumulate quietly — and compound until they choke a lab’s ability to grow and erode its profitability.
I spent 12+ years at every layer of the molecular workflow working to support the wet lab, and in the process developed a deep passion for the work labs do. Unusually, I had the opportunity to hold product responsibility for most of it at once — not as a bench scientist or a software engineer, but as the person who had to make the whole system make sense. I’m excited to bring that experience to HelixWrks.
Two ways to close the gap.
Advisory — bring me in
Fixed-scope, outcomes-not-hours engagements that diagnose the gap, de-risk the decision, and build the business case — before you commit. We work the problem together, and the deliverables are yours to keep.
Explore Advisory →LIMS Readiness Assessment
The same thinking, productized — score your lab across 10 domains before you commit to an implementation. Alpha members get first access and a hand in shaping what ships next.
Explore HelixWrks Lab →Featured thinking
Three featured articles. The full library — including interactive frameworks — lives on the Content & Resources page.
Why LIMS Implementations Fail
Six patterns that play out repeatedly across genomics, molecular diagnostics, and clinical lab environments. The culprit is almost never the technology.
Read →Laboratory Technical Debt
High-throughput platforms sitting at 40% utilization. Leadership won’t approve expansion. The overhead per sample makes growth uneconomical. How technical debt accumulates — and the path out.
Read →End-to-End Workflow Strategy in Clinical Labs
How to right-size your E2E architecture for your stage of growth, find your rate-limiting steps before you buy anything, and reframe your lab as a profit center.
Read →